Pharmed Pharmaceuticals Pty Ltd has acquired Amalgamated Pharmaceuticals Ltd
Pharmed Pharmaceuticals (Pty) Ltd (Pharmed) has acquired the business assets (excluding debtors and liabilities) of Amalgamated Pharmaceuticals Ltd (Amalgamated), a pharmaceutical wholesale and distribution company, for an undisclosed consideration.
Pharmed is a supplier and distributor of healthcare related products, including ethical, generic, patent, homeopathic, surgical, dental and veterinary products and medical equipment, reagents and supplies to dispensing doctors, retail pharmacies, private hospitals and other allied healthcare professionals. The acquisition of the Amalgamated business meets Pharmed’s strategic growth objective.
Amalgamated was formed in 1997 by the merger of five major pharmaceutical distribution companies, which boasted a track record of more than 60 years’ service. Amalgamated is a full-line, nation-wide wholesaler that is focused exclusively on the pharmaceutical market with its head office in Johannesburg and a satellite office in Durban.
Oaklins' team in South Africa acted as financial advisor to Pharmed in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more